S1PR3 expression independently predicts the cumulative incidence of relapse in adult B-cell acute lymphoblastic leukemia: a single-center retrospective analysis
A bone marrow protein marker predicts which ALL patients face highest relapse risk, supporting smarter upfront treatment tailoring.
In 285 adult B-ALL patients, elevated bone marrow S1PR3 expression independently predicted 3-year cumulative incidence of relapse with AUC 0.887 in ROC analysis. High S1PR3 was associated with adverse clinical features and Kaplan-Meier curves demonstrating significantly higher relapse rates, establishing it as a novel biomarker for risk stratification.
What the study was
- Study design
- Retrospective cohort with biomarker validation
- Population
- Adult B-ALL patients and healthy controls, single center Xinjiang, China
- Sample size
- 285
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- American Journal of Clinical Pathology
Why it surfaced
Novel biomarker (S1PR3) for B-ALL relapse prediction with good AUC; n=285 is respectable; single-center and retrospective design limits generalizability; independent validation needed.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.